Jul 25, 2017
TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399
TLC (4152:TT) is due to receive a government subsidy of NT$30,903,000 from Taiwan’s Ministry of Economic Affairs (MOEA) towards its Fast Track designation plan for ophthalmology product candidate TLC399. The grant will be allocated in installments over the 36 months of planned development and used for the TLC399 Phase 2 trial currently enrolling patients at multiple sites in the U.S.
The grant is administered by a division of MOEA’s Department of Industrial Technology, the Research and Development Organization Technology Development Program, dedicated to the development of forward-looking and key industrial technologies with the aim of improving Taiwan’s R&D environment and infrastructure. The TLC399 program satisfied these objectives and qualified to receive a subsidy. With potential to become a mainstay of treatment for macular edema, should it obtain regulatory approval, TLC399 will not only contribute to Taiwanese industrial capabilities but also enhance quality of life for patients around the world.
Common limitations of existing treatments for macular edema include short duration of effect, need for implant removal from the eye, or large needle size for injection, which may lead to infections and complications. TLC399, a liposomal encapsulated dexamethasone using TLC’s proprietary BioSeizer™ technology, is designed to address these limitations. TLC399 has shown sustained release capabilities without any implants in the eye. In addition, a much smaller needle can be used for injection, reducing the risk of infections and complications.
TLC is currently enrolling patients in the TLC399 Phase 2 clinical trial at multiple sites in the U.S. For more information on this trial, please visit https://clinicaltrials.gov/ct2/show/study/NCT03093701.
Source：Taiwan Liposome Company, Ltd.
http://www.tlcbio.com/en-global/MediaDownloadContent/media_download/Content/92